AZN's Imfinzi Gets EU Nod for Limited-Stage Small-Cell Lung Cancer

AstraZeneca (AZN) recently announced that the European Commission has approved its blockbuster cancer drug Imfinzi (durvalumab) as monotherapy for treating limited-stage small cell lung cancer (LS-SCLC) in adult patients whose disease has not progressed following platinum-based chemoradiation therapy (CRT).The latest approval for Imfinzi in the European Union (EU) was based on data from the phase III ADRIATIC study.Data from the phase III ADRIATIC study showed that treatment with Imfinzi reduced the risk of ...